Ha Tay Pharmaceutical JSC
HHNX:DHT49,900.00
VND
-100.00
(-0.20%)
ISIN
VN000000DHT3
Return %
Stock
S&P 500
1Y
-31.31
14.20
3Y
195.98
81.12
5Y
259.70
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Thang Xuan Le
- Full Time Employees
- 586
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ha Noi Vietnam
- IPO Date
- Dec 3, 2008
- Website
- hataphar.com.vn
- Similar Companies
- Business
- Ha Tay Pharmaceutical Joint Stock Company (Hataphar) is a Vietnam-based pharmaceutical company primarily engaged in the research, development, manufacturing, processing, trading, import, and export of finished pharmaceuticals, active pharmaceutical ingredients, medicinal herbs, dietary supplements, and medical supplies. Founded in 1965 and headquartered in Hanoi, Vietnam, the company operates across the healthcare, pharmaceutical manufacturing, and commercial distribution sectors. The company's core product portfolio encompasses a diverse range of therapeutic categories, including antibiotics, antibacterial, and antiviral agents; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs; cardiovascular, antihypertensive, and metabolic therapeutics; respiratory, antitussive, and antihistaminic medicines; gastrointestinal, digestive, and hepatobiliary formulations; neurological, musculoskeletal, and psychiatric treatments; dermatological preparations, creams, and topical ointments; traditional herbal medicines and phytopharmaceuticals; effervescent tablets, multivitamins, and dietary health supplements; and hospital medical supplies, clinical consumables, and diagnostic materials. In addition to commercializing proprietary and generic branded formulations, the company provides contract manufacturing (OEM/ODM), private-label pharmaceutical formulation, packaging, laboratory quality testing, cold-chain warehousing, and wholesale pharmaceutical distribution services to hospitals, healthcare centers, retail pharmacy networks, and institutional clients across Vietnam and select export markets in Southeast Asia. In recent major corporate developments, the company strengthened its strategic alliance with Japanese drugmaker ASKA Pharmaceutical Co., Ltd., which expanded its equity investment to become the company's leading foreign strategic shareholder. In coordination with ASKA Pharmaceutical, the company advanced the construction and operational deployment of its high-tech pharmaceutical manufacturing facility at the Hoa Lac Hi-Tech Park in Hanoi, developed to meet stringent Japan-GMP and PIC/S-GMP international quality standards. This strategic expansion is designed to facilitate advanced pharmaceutical technology transfer, expand sterile and high-potency oral solid dosage capacities, upgrade regulatory compliance for prescription drug portfolios, and position the company as an export-oriented manufacturing hub for Japan and other high-standard global markets.